Literature DB >> 18156727

Apolipoprotein e polymorphism in ischemic stroke patients with different pathogenetic origins.

So Young Kang1, Woo In Lee.   

Abstract

BACKGROUND: The association of apolipoprotein E (apoE) polymorphism with interindividual variability of serum lipid concentrations and the initiation and progression of atherosclerosis is inconclusive. This study was performed to explore the associations of apoE with lipid concentrations and ischemic stroke in patients with large artery atherosclerosis (LAA) subgroup or without atherosclerotic vascular lesions (small artery occlusion, SAO) subgroup through a case-control study among the Korean population.
METHODS: The ischemic stroke group (n=194) was subdivided into an LAA subgroup (n=112) and a SAO without atherosclerotic lesion subgroup (n=82). An age-matched healthy control group (n=168) was recruited. Serum lipid concentrations were measured and apoE genotypes were determined by real-time PCR and melting curve analysis with the LightCycler (Roche Diagnostics).
RESULTS: The frequency of the epsilon4 carriers was significantly higher in the ischemic stroke group (22.7%) than in the control group (11.9%) (P=0.01). However, the frequency of epsilon4 carriers showed no difference between the LAA and SAO subgroups (22.3% vs 23.2%, P=0.89). The adjusted low density lipoprotein cholesterol (LDLc) concentration was significantly higher in ischemic stroke group than in control group (P=0.04), but showed no significant differences in all lipid concentrations between the LAA and SAO subgroups. LDLc concentrations were lower in epsilon2 carriers than in epsilon3 and epsilon4 alleles, but showed no difference between the epsilon4 carriers and epsilon3 allele.
CONCLUSIONS: Although there was an association between the epsilon4 allele and ischemic stroke and between the LDLc concentration and ischemic stroke, there was no significant difference in the lipid concentrations and distribution of apoE genotypes between the LAA and SAO subgroups. Therefore, the epsilon4 allele may have different effects on the ischemic stroke that are independent of the atherosclerotic mechanism by high LDLc concentration.

Entities:  

Year:  2006        PMID: 18156727     DOI: 10.3343/kjlm.2006.26.3.210

Source DB:  PubMed          Journal:  Korean J Lab Med        ISSN: 1598-6535


  6 in total

1.  Does the geographical gradient of ApoE4 allele exist in China? A systemic comparison among multiple Chinese populations.

Authors:  Peng Hu; Yuan Han Qin; Cheng Xue Jing; Ling Lu; Bo Hu; Peng Fei Du
Journal:  Mol Biol Rep       Date:  2010-03-31       Impact factor: 2.316

Review 2.  Association between Apolipoprotein ε4 Gene Polymorphism and Risk of Ischemic Stroke: A Meta-Analysis.

Authors:  Amit Kumar; Pradeep Kumar; Manya Prasad; Shubham Misra; Awadh Kishor Pandit; Kamalesh Chakravarty
Journal:  Ann Neurosci       Date:  2016-07-07

3.  Apolipoprotein E ε4 Polymorphism as a Risk Factor for Ischemic Stroke: A Systematic Review and Meta-Analysis.

Authors:  Su-Ya Qiao; Ke Shang; Yun-Hui Chu; Hai-Han Yu; Xin Chen; Chuan Qin; Deng-Ji Pan; Dai-Shi Tian
Journal:  Dis Markers       Date:  2022-02-03       Impact factor: 3.434

4.  Assessment of two missense polymorphisms (rs4762 and rs699) of the angiotensinogen gene and stroke.

Authors:  Hyun-Kyung Park; Myung-Chun Kim; Sung-Min Kim; Dae Jean Jo
Journal:  Exp Ther Med       Date:  2012-01-11       Impact factor: 2.447

5.  Identification of PSEN1 and APP gene mutations in Korean patients with early-onset Alzheimer's disease.

Authors:  Hyun-Kyung Park; Duk Lyul Na; Jae-Hong Lee; Jong-Won Kim; Chang-Seok Ki
Journal:  J Korean Med Sci       Date:  2008-04       Impact factor: 2.153

6.  Interleukin-6 Receptor Polymorphisms Contribute to the Neurological Status of Korean Patients with Ischemic Stroke.

Authors:  Dong Hwan Kim; Seung Don Yoo; Jinmann Chon; Dong Hwan Yun; Hee-Sang Kim; Hae Jeong Park; Su Kang Kim; Joo-Ho Chung; Jin Kyu Kang; Seung Ah Lee
Journal:  J Korean Med Sci       Date:  2016-02-16       Impact factor: 2.153

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.